The Bio/Pharma Beat

    View Author July 2020

    In this edition of the Bio/Pharma Beat we highlight the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions from June 2020, including:

    • The Federal Circuit holds it does not have statutory authority to award attorney fees in IPR proceedings
    • A district court holds that obtaining and enforcing the Humira “patent thicket” did not violate antitrust laws
    • A district court finds a lack of written description support where the patentee attempted to claim a later-made invention in an earlier filed application in order to gain the benefit of the earlier filing date